3-substituted oxindole β3 agonists

US7087635B2 · kind B2 · utility

Assignee

• ELI LILLY AND COMPANY · US

Inventors

• Daniel Jon Sall · Greenwood, US
• Jolie Anne Bastian · Indianapolis, US
• Cynthia Darshini Jesudason · Indianapolis, US
• Don Richard Finley · Greenwood, US
• Freddie Craig Stevens · Indianapolis, US
• Vincent Patrick Rocco · Indianapolis, US
• Patrick Gianpietro Spinazze · Avon, US
• John Xiaoqiang He · Fishers, US
• John A. Werner · Antioch, US
• William George Trankle · Southport, US
• Andrew Michael Ratz · Greenwood, US
• Theo Schotten · Winsen (Luhe), DE
• Gerd Reuhter · Hamburg, DE

Key dates

• Filing date: Mar 16, 2005
• Grant date: Aug 8, 2006
• Expiry date: May 7, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a β3 adrenergic receptor agonist of formula I:or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.